Back to Journals » OncoTargets and Therapy » Volume 9

Trastuzumab in the management of gastroesophageal cancer: patient selection and perspectives

Authors Davidson M, Starling N

Received 16 August 2016

Accepted for publication 5 November 2016

Published 25 November 2016 Volume 2016:9 Pages 7235—7245

DOI https://doi.org/10.2147/OTT.S100643

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Akshita Wason

Peer reviewer comments 3

Editor who approved publication: Dr XuYu Yang


Michael Davidson, Naureen Starling

Department of Gastrointestinal Oncology, The Royal Marsden Hospital NHS Foundation Trust, London, UK

Abstract: The addition of trastuzumab to the treatment of a subset of patients with advanced gastric and gastroesophageal junction cancers showing HER2 positivity has been shown to confer clinical benefit; however, questions remain over the optimal methods for defining and selecting such patients. This review provides an overview of current standards for assessing HER2 positivity, the evolving treatment landscape for HER2-positive gastric and esophageal cancers and the challenges and potential future directions in optimal patient selection for HER2-targeted therapy.

Keywords:
HER2, trastuzumab, gastric cancer, immunohistochemistry, in situ hybridization

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]